NID1

Across TCGA pan-cancer cohorts, NID1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NID1 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NID1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NID1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where NID1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.765	0.401	.002	23	view →
LUAD	OS	Median	III,IV	0.223	0.618	.009	17	view →
LSCC	DFS	Median	II,III,IV	0.813	1.000	.001	10	view →
PDAC	DFS	Median	All	0.876	0.711	.027	4	view →
HNSC	OS	Quartile	II,III,IV	0.932	1.000	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NID1–CCRCC (DFS)

Open the CCRCC breakdown →